PHP170 The Swiss Health Technology Assessment (HTA) Consensus: Guiding Principles

Abstract

guideline and the shortly coming updated version is an appropriate time to review and compare it with other European guidelines in order to identify the main similarities and differences in key features. METHODS: We chose 14 European guidelines and compared them based on the 32 key guideline features developed by Hjelmgren et al. RESULTS: No relevant differences were found between the Hungarian and the European guidelines in tha major part (23) of the key features. The Hungarian guideline represented nearly the same methodological aspects for example in the choice of comparator, time horizon, discount rate and financial impact analysis. We appraised relevant differences in the perspective of the PE studies, preferred analytical technic (CMA, CEA, CUA, CBA), systematic review of evidences, costs to be included, preferred outcome measure and deliver utility. The QALY is the preferred health outcome measure in cost utility studies almost in every European countries, however only the English and Scottish guidelines require only EQ-5D profile to deliver utility. In the new version of the Hungarian guideline the discount rate will be changed from 5% to 3,7%, the cost-effectiveness threshold will be explicitly determined (twofold and threefold of GDP per capita) and the direct comparisons will be preferred instead of indirect comparisons. CONCLUSIONS: Generally we concluded that the Hungarian guideline published in 2002 and also the new modified version basicly require the same approach and expectations as the European ones. Change in three main things (discount rate, cost-effectivess threshold, direct comparison preference) makes our guidelines more elaborated that could help the rational decision-making. The explicitly determined cost-effectiveness threshold requires specification in the method of delivering utility in the future.

The Social Benefit of Animal Testing

“…Die systematische Bewertung medizinischer Verfahren und Technologien wird international unter dem Begriff "health technology assessments" (HTA) zusammengefasst und für politische und wirtschaftliche Entscheidungen herangezogen. Bei medizinischen Interventionen beziehen beispielsweise Krankenversicherungen in ihre Evaluationsmethoden hilfreiche Parameter wie subjektive individuelle therapeutische Effekte und Lebensqualität, Public-Health-Nutzen aus der individuellen Perspektive Dritter und den sozioökonomischen Nutzen einschließlich indirekter volkswirtschaftlicher Folgen mit ein (Schlander et al, 2011). So kann bspw.…”